TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06316518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness group
Description: In the study, primigravidas will receive 8-module (8-week-long) trainings, each lasting approximately 45 minutes, 3 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness group
Description: In the study, primigravidas will receive 8-module (8-week-long) trainings, each lasting approximately 45 minutes, 3 days a week.
Study: NCT05895357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musictherapy
Description: The patients were asked about the type of music they wanted to listen to. Especially in the last meta-analyses, it was determined that listening to the music that patients chose was more effective (Witten 2020). For this reason, after the intervention group is asked about the music they want to listen to, the music they want will be played from the music application.
Study: NCT00681148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox injection
Description: Intraprostatic injection of Botox (100 units for \< 30 cc prostate; 200 units for \> 30 cc prostate) administering 2 transperineal injections into both lateral lobes of the prostate (25-50 units per injection), just 5-10 mm proximal to the bladder neck.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Saline injection, administering 2 transperineal injections into both lateral lobes of the prostate (1-2 cc per injection), just 5-10 mm proximal to the bladder neck.
Study: NCT06131151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: Nerve block in percutaneous nephrolithotomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: Nerve block in percutaneous nephrolithotomy
Study: NCT05063877

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EQU-001
Description: EQU-001 in 10 mg and 20 mg capsules
Study: NCT04487678

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester supplement
Description: Participants taking part in this study will receive a drink containing either 141 or 282 mg/kg bodyweight of ketone esters in a randomised order. These doses are in line with recommendations by the company HVMN from which the supplements for this study will be obtained.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester supplement
Description: Participants taking part in this study will receive a drink containing either 141 or 282 mg/kg bodyweight of ketone esters in a randomised order. These doses are in line with recommendations by the company HVMN from which the supplements for this study will be obtained.
Study: NCT06222827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab Prefilled Syringe
Description: Satralizumab is supplied as prefilled syringe with 1 millimeter of solution for subcutaneous injection corresponding to 120mg of satralizumab. During the first period (double blind period), satralizumab will be administered at weeks 0, 2, 4 and every 4 weeks until week 48. During the second period (open label period), satralizumab will be administered at weeks 48, 50, 52 and every 4 weeks until week 96.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo prefilled syringe is identical in composition to satralizumab, but does not contain the satralizumab active agent. It is identical in appearance and packaging to satralizumab. During the first period (double blind period), placebo will be administered at weeks 0, 2, 4 and every 4 weeks until week 48. During the second period (open label period), satralizumab will be administered at weeks 48, 50, 52 and every 4 weeks until week 96.
Study: NCT04862442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong exercises
Description: Specific Qigong exercises 1- Painting the rainbow 2-Raising the arms 3-Looking at the moon 4- Pushing the waves

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong exercises
Description: Specific Qigong exercises 1- Painting the rainbow 2-Raising the arms 3-Looking at the moon 4- Pushing the waves
Study: NCT06013631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis Training
Description: Training for prostheses at the appropriate amputation level will be provided. Conventional gait training protocols include Tandem walk, within parallel bar, controlled environment, full length Mirror on one side, weight shifting, shifting onto the Prosthetic Side, Pelvic 22 rotation, Stepping on multiple heights and positions, Tandem walk, within parallel bar, and weight shifting. Gait training will last six weeks in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phantom Exercises
Description: The phantom exercises involved visualizing and then trying to perform the movements of the phantom limb.
Study: NCT05766527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KM602
Description: Multiple dose levels of KM602 will be administered, including 0.01 mg/kg QW, 0.1 mg/kg QW, 0.6 mg/kg QW, 3 mg/kg QW, and 10 mg/kg QW. KM602 is administered intravenously once a week, and each cycle is 21 days.
Study: NCT06329323

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Serum and plasma microRNA quantification

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Serum and plasma microRNA quantification

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Serum and plasma microRNA quantification

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Serum and plasma microRNA quantification

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Serum and plasma microRNA quantification

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathology specimen miRNA expression
Description: Pathology specimen mirNA expression - ALL MOGCT; OPTIONAL for BOGCT

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathology specimen miRNA expression
Description: Pathology specimen mirNA expression - ALL MOGCT; OPTIONAL for BOGCT

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathology specimen miRNA expression
Description: Pathology specimen mirNA expression - ALL MOGCT; OPTIONAL for BOGCT

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathology specimen miRNA expression
Description: Pathology specimen mirNA expression - ALL MOGCT; OPTIONAL for BOGCT
Study: NCT06208904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of GIPRA
Description: Intravenous infusion of GIP(3-30)NH2 in a concentration of 1,000 pmol/kg/min during experimental days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion of saline
Description: Intravenous infusion of isotonic saline 9 mg/ml added 0,5% human serum albumin during experimental days
Study: NCT06179147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical traction
Description: Traction of the uterine cervix applied in the study; It is the process of pulling the anterior and posterior lips of the cervix towards the intraoitus, downwards and backwards for approximately 90 seconds using overpens. Traction is applied until the cervix reaches the level of vaginal introitus. It is a cost-effective, new, simple intervention with no reported adverse effects.
Study: NCT03729427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane block for patents undergoing rib cartilage grafting surgeries
Study: NCT06236321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast Field Cycling MRI scan
Description: Three scans to be done over the period of cancer treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provision of saliva and faecal samples
Description: Three times over the period of cancer treatment
Study: NCT06605846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: otago excercises
Description: Otago training is helpful, and one of the most powerful interventions where the original randomized controlled trials reported improvements in functional outcomes and a 35% reduction in falls for frail, high-risk older adults (Shubert et al., 2018). In Egypt, there are little researches about Otago Exercise Program.~Exercise is well-known as an economic and key adjuvant treatment in clinical oncology that improves QOL of cancer survivors. Many studies focused on investigating the benefits of exercise interventions on preventing falls and improving physical performance of older adults. Combination of strength and functional balance exercise has been demonstrated as an effective method to improve balance performance, rather than strength training alone

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Medical ADT treatment
Description: Medical ADT treatment according to patient age, prostatic cancer stage
Study: NCT06508203

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthrocentesis with lactate ringer only
Description: classical arthrocentesis with lactate ringer only (control group).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthrocentesis with lactate ringer followed by injection with piroxicam 2 ml (40mg)
Description: classical arthrocentesis with lactate ringer followed by injection with piroxicam 2 ml (40mg)
Study: NCT06610643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination therapy
Description: A combination of 5-day remdesivir and 10-day Nirmatrelvir/Ritonavir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard of care
Study: NCT06609278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: harm reduction intervention
Description: Each participant will complete a pre-test at Study Visit 1 prior to the intervention, participate in the intervention, then complete a post-test. After the intervention, participants will participate in a recorded focus group. Participants will be offered FTS, Narcan, first aid supplies at the study visit.
Study: NCT06611865

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraligamentary anaesthesia
Description: Injection of anesthetic solution into the intraligamentary space along the long axis of a tooth root using a pressure syringe.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraligamentary anaesthesia
Description: Injection of anesthetic solution into the intraligamentary space along the long axis of a tooth root using a pressure syringe.
Study: NCT05951270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple Polyphenols
Description: ApplePhenon® is prepared from unripe green apples (malus domestica) and contains a large amounts of polyphenols. The supplement contains 63.8% procyanidins, 12.4% flavon-3-ols, 6.5% chalcones and 10.8% phenolcarboxylic acids

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The placebo used in this study is 1100 mg maltodextrin (Avebe, Veendam, the Netherlands). This product is an enzymatically converted potato starch. The flavor and color will have a similar/identical appearance and taste as all mentioned antioxidants.
Study: NCT05688631

Intervention type: OTHER
Intervention: Dietary antioxidant intake
Description: Decreased intake of dietary antioxidant is associated with decreased thiol disulfide homeostasis parameters in diabetic and healthy participants.

Intervention type: OTHER
Intervention: Dietary antioxidant intake
Description: Decreased intake of dietary antioxidant is associated with decreased thiol disulfide homeostasis parameters in diabetic and healthy participants.
Study: NCT06349447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED
Description: 308 nm LED light was utilized to induce an vivo PIE/PIH model on the thigh of subjects. The irradiation dose was 1.5 MED. Five circular experimental lesions measuring 1.5 × 1.5 cm were selected on the thighs, categorizing into five groups: control group, 830 nm LED treatment group, 590 nm LED treatment group, 830 nm LED prevention group and 590 nm LED prevention group. 830 nm LED and 590 nm LED were irradiated, respectively. For therapeutic irradiation, the PIH model was induced on D1, and 830 nm (60 J/cm2, 50 mW/cm2) and 590 nm LED (20 J/cm2, 20 mW/cm2) were irradiated on D0, D1, D3, D6 and D8, respectively. For preventive irradiation, 830 nm and 590 nm LED were irradiated on D0, D1, D3, D6 and D8, respectively, and the PIE/PIH model was induced on D9.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without any LED exposition
Description: without any LED exposition
Study: NCT06611865

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior alveolar nerve block
Description: Anaesthetic injection into the pterygomandibular space to block the Inferior alveolar nerve at the mandibular foramen point.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior alveolar nerve block
Description: Anaesthetic injection into the pterygomandibular space to block the Inferior alveolar nerve at the mandibular foramen point.
Study: NCT06612476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin 6-guided antibiotic therapy
Description: In Interleukin-6 group, antibiotic prescription decisions will made according to the results of IL-6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GOLD-guided antibiotic therapy
Description: In guideline group, antibiotic prescription decisions will made according to the recommendations of GOLD guideline.
Study: NCT06612814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Parp inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalpiciclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant/AI
Description: Endocrine therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant/AI
Description: Endocrine therapy
Study: NCT06612060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac surgery with the use of extracorporeal circulation
Description: All randomized patients will undergo open heart surgery with the use of extracorporeal circulation. Criteria for randomization: i) age between 18 and 80 years and ii) elective procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac surgery with the use of extracorporeal circulation
Description: All randomized patients will undergo open heart surgery with the use of extracorporeal circulation. Criteria for randomization: i) age between 18 and 80 years and ii) elective procedure.
Study: NCT06612996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Intravenous tramadol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Description: Intravenous magnesium sulphate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline
Study: NCT06612658

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A novel, proprietary encapsulated form of Capsicum extract in beadlet form standardized to 2% capsaicinoids
Description: This study will investigate the effect of the supplement on exercise performance.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: A novel, proprietary encapsulated form of Capsicum extract in beadlet form standardized to 2% capsaicinoids
Description: This study will investigate the effect of the supplement on exercise performance.
Study: NCT06453733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crainio
Description: Crainio device comprises a forehead-mounted sensor containing infrared light sources that can illuminate the deep brain tissue of the frontal lobe. Photodetectors in the sensor detect the backscattered light, which is modulated by pulsation of the cerebral arteries. A control unit processes the backscattered light (called the photoplethysmogram, PPG) and transmits it to a computer device to train ML models that will estimate ICP offline.
Study: NCT06467604

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Participants will be provided electronic surveys at 3 timepoints throughout study.

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Participants will be provided electronic surveys at 3 timepoints throughout study.

Intervention type: OTHER
Intervention: Indirect Calorimetry
Description: Participants will receive indirect calorimetry at 3 time points throughout the study.

Intervention type: OTHER
Intervention: Indirect Calorimetry
Description: Participants will receive indirect calorimetry at 3 time points throughout the study.

Intervention type: OTHER
Intervention: Body composition
Description: Participants will receive body scans using bioelectrical impedence seca mBCA 554 digital body composition analysis scale 3 time points throughout the study.

Intervention type: OTHER
Intervention: Body composition
Description: Participants will receive body scans using bioelectrical impedence seca mBCA 554 digital body composition analysis scale 3 time points throughout the study.

Intervention type: OTHER
Intervention: Anthropometrics
Description: Participants will have their Height, weight, waist circumference, and calculated BMI performed at 3 time points throughout the study.

Intervention type: OTHER
Intervention: Anthropometrics
Description: Participants will have their Height, weight, waist circumference, and calculated BMI performed at 3 time points throughout the study.
Study: NCT06204770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extensive hydrolyzed protein formula
Description: NR Pepti is infant formula for special medical purposes based on extensive hydrolyzed whey protein for infants aged 0-12 months. This milk is intended for cow's milk protein allergy. This product is lactose free with medium chain triglycerides (MCT)
Study: NCT05231889

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silverway guidewire
Description: The Silverway guidewire is a newly developed guidewire to overcome the problems the Radifocus guidewire has

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radifocus guidewire
Description: The Radifocus guidewire is a hydrophilic coated guidewire that is used when a standard J-tip guidewire does not cross a vascular anomaly
Study: NCT06432478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed custom applicator
Description: 3D-printed custom applicator
Study: NCT05828953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Drug: Anlotinib The dose of nintedanib hydrochloride is 8mg per dose, taken orally once daily before breakfast. The drug is taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.~Drug: Placebo Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.
Study: NCT05886842

Intervention type: OTHER
Intervention: Test-retest
Description: Test-retest
Study: NCT06487715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel (260 mg/m2, d1)
Description: 260 mg/m2, d1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 80 mg/m2, d1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: 200 mg, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: First two cycles : intraperitoneally 7.5 mg/m2 Maintenance period: intravenously 7.5 mg/m2
Study: NCT05707390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days
Study: NCT06117020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTR-601
Description: Safety and tolerability of oral MTR-601, a highly selective fast twitch myosin 2 ATPase inhibitor in normal healthy volunteers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTR-601
Description: Safety and tolerability of oral MTR-601, a highly selective fast twitch myosin 2 ATPase inhibitor in normal healthy volunteers
Study: NCT05306717

Intervention type: OTHER
Intervention: Questionnaire
Description: The study will compare the rates of isolation and restraint of the two sectoral admission units welcoming people in care without consent for a period of one year. The impact of the QPGE on the satisfaction scores will be systematically evaluated by a self-questionnaire for patients at the end of hospitalization. The QPGE is administered by a nurse during the reception interview of the patient in the unit.
Study: NCT05819372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zygomaticomaxillary fracture repair
Description: A cone beam CT (CBCT) scan of the patient will be used to create a 3D scanned image of zygomaticomaxillary complex fracture (ZMC)~* 3D images will be introduced to finite element (FA) software to evaluate Stresses (MPa), Micromotion (microns), and Life time (cycle) For each model and determine which point of fixation is the best~* After application this point of fixation on the patient~* Finite element analysis will be done again to verify the previous results
Study: NCT05418907

Intervention type: RADIATION
Intervention: 68Ga-NODAGA-exendin-4 PET/CT
Description: PET/CT imaging 1 hour after injection of 100 MB 68Ga-NODAGA-exendin-4
Study: NCT05676788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperspectral Imaging
Description: Identification of the intersegmental plane